KNKenna Nagy

Kenna Nagy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kenna Nagy has a total of 58 co-authors. Here are the top co-authors by number of shared publications:

  • Mansun Law

    Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, USA

    4 shared publications
  • Erick Giang

    Department of Immunology and Microbiology, the Scripps Research Institute, La Jolla, CA 92037, USA

    3 shared publications
  • Ian A. Wilson

    Department of Integrative Structural and Computational Biology, The Scripps Research Institute

    3 shared publications
  • Netanel Tzarum

    Department of Biological Chemistry, Alexander Silberman Institute of Life Sciences, Faculty of Mathematics & Science, The Hebrew University of Jerusalem, Jerusalem, Israel

    3 shared publications
  • Anne Costanzo

    Department of Immunology and Microbiology, Scripps Research , La Jolla, CA

    2 shared publications
  • Fang Chen

    Department of Immunology and Microbiology, the Scripps Research Institute, La Jolla, CA 92037, USA

    2 shared publications

Latest Publications

  • Open Access

    The Qβ bacteriophage nanoparticle contributes to the adjuvanticity of antiglycan vaccines through a unique inflammatory pathway

    by Kenna Nagy, Jeffery Noble, Shenglou Deng, Robert Hincapie, Anne Costanzo, Lisa Kain, Paul B Savage, M G Finn, Luc Teyton

    Current glycoconjugate vaccines often fail to induce durable B cell memory or to provide sufficiently high-affinity antibodies limiting their utility for prophylactic protection against most bacterial and fungal pathogens. We address this limitation by engineering a chemically functionalized protein nanoparticle vaccine capable of eliciting protective nanomolar affinity antiglycan antibodies and long-term humoral memory. This platform incorporates a combination of two B cell–focused adjuvants, a TLR7 agonist and a natural killer T cell agonist, in order to enhance the antiglycan antibody maturation and memory formation. To define the contributions of each pathway, the antiglycan responses were evaluated at early and late time points following immunization. Although mice deficient in both TLR7 and natural killer T cell signaling revealed diminished primary immunization responses, an unexpectedly robust antiglycan antibody titer still developed and persisted for at least 1 yr after a two-dose immunization. These results indicate that durable antiglycan humoral immunity can develop independent of the chosen adjuvant pathways and may be driven by intrinsic adjuvanticity of the recombinant bacteriophage nanoparticle. Mechanistically, this effect was associated with an inflammatory response in which IFNγ and IL-1α appeared to play important roles. Together, these findings identify a previously unappreciated component contributing to long-term antiglycan immunity and support the use of bacteriophage-derived nanoparticles as platforms for vaccines against emerging antibiotic-resistant microorganisms.

  • Open Access

    Repositioning the Early Pathology of Type 1 Diabetes to the Extraislet Vasculature

    by Anne Costanzo, Don Clarke, Marie Holt, Siddhartha Sharma, Kenna Nagy, Xuqian Tan, Lisa Kain, Brian Abe, Sandrine Luce, Christian Boitard, et al.

    Type 1 diabetes (T1D) is a prototypic T cell–mediated autoimmune disease. Because the islets of Langerhans are insulated from blood vessels by a double basement membrane and lack detectable lymphatic drainage, interactions between endocrine and circulating T cells are not permitted. Thus, we hypothesized that initiation and progression of anti-islet immunity required islet neolymphangiogenesis to allow T cell access to the islet. Combining microscopy and single cell approaches, the timing of this phenomenon in mice was situated between 5 and 8 wk of age when activated anti-insulin CD4 T cells became detectable in peripheral blood while peri-islet pathology developed. This “peri-insulitis,” dominated by CD4 T cells, respected the islet basement membrane and was limited on the outside by lymphatic endothelial cells that gave it the attributes of a tertiary lymphoid structure. As in most tissues, lymphangiogenesis seemed to be secondary to local segmental endothelial inflammation at the collecting postcapillary venule. In addition to classic markers of inflammation such as CD29, V-CAM, and NOS, MHC class II molecules were expressed by nonhematopoietic cells in the same location both in mouse and human islets. This CD45− MHC class II+ cell population was capable of spontaneously presenting islet Ags to CD4 T cells. Altogether, these observations favor an alternative model for the initiation of T1D, outside of the islet, in which a vascular-associated cell appears to be an important MHC class II–expressing and –presenting cell.


  • Open Access

    An alternate conformation of HCV E2 neutralizing face as an additional vaccine target

    by Netanel Tzarum, Erick Giang, Rameshwar U. Kadam, Fang Chen, Kenna Nagy, Elias H. Augestad, Rodrigo Velázquez-Moctezuma, Zhen-Yong Keck, Yuanzi Hua, Robyn L. Stanfield, et al.

    To achieve global elimination of hepatitis C virus (HCV), an effective cross-genotype vaccine is needed. The HCV envelope glycoprotein E2 is the main target for neutralizing antibodies (nAbs), which aid in HCV clearance and protection. E2 is structurally flexible and functions in engaging host receptors. Many nAbs bind to the “neutralizing face” on E2, including several broadly nAbs encoded by the VH1-69 germline gene family that bind to a similar conformation (A) of this face. Here, a previously unknown conformation (B) of the neutralizing face is revealed in crystal structures of two of four additional E2–VH1-69 nAb complexes. In this conformation, the E2 front-layer region is displaced upon antibody binding, exposing residues in the back layer for direct antibody interaction. This E2 B structure may represent another conformational state in the viral entry process that is susceptible to antibody neutralization and thus provide a new target for rational vaccine development.


  • Open Access

    Proof of concept for rational design of hepatitis C virus E2 core nanoparticle vaccines

    by Linling He, Netanel Tzarum, Xiaohe Lin, Benjamin Shapero, Cindy Sou, Colin J. Mann, Armando Stano, Lei Zhang, Kenna Nagy, Erick Giang, et al.

    An HCV vaccine strategy displays optimized E2 cores on nanoparticles for eliciting a cross-neutralizing B cell response.


  • Antibody Responses to Immunization With HCV Envelope Glycoproteins as a Baseline for B-Cell–Based Vaccine Development

    by Fang Chen, Kenna Nagy, Deborah Chavez, Shelby Willis, Ryan McBride, Erick Giang, Andrew Honda, Jens Bukh, Phillip Ordoukhanian, Jiang Zhu, et al.


  • Open Access

    Immunogenetic and structural analysis of a class of HCV broadly neutralizing antibodies and their precursors

    by Fernando Aleman, Netanel Tzarum, Leopold Kong, Kenna Nagy, Jiang Zhu, Ian A. Wilson, Mansun Law

    Significance: Hepatitis C virus (HCV) infects 1–2% of the world’s population, but a vaccine to limit spreading of this silent killer is unavailable. A leading strategy in vaccine design to counter the genetic variability of HCV is to elicit broadly neutralizing antibodies (bnAbs) targeting conserved viral epitopes. The HCV antigenic site 412–423 (AS412) is highly conserved and a prime vaccine target. In this study, the genetic and structural properties of murine bnAbs targeting AS412 were determined. Using specific molecular interactions encoded in the antibody germline genes and those acquired by somatic hypermutation, two distinct antibody lineages recognize AS412 in near identical conformations. The results provide key insights in the development of HCV bnAbs for rational vaccine design.